Equities

Hisamitsu Pharmaceutical Co Inc

Hisamitsu Pharmaceutical Co Inc

Actions
  • Price (EUR)26.00
  • Today's Change0.20 / 0.78%
  • Shares traded--
  • 1 Year change-5.11%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Hisamitsu Pharmaceutical Co Inc grew revenues 10.42% from 128.33bn to 141.71bn while net income improved 18.97% from 11.74bn to 13.97bn.
Gross margin56.42%
Net profit margin10.10%
Operating margin8.61%
Return on assets4.36%
Return on equity5.36%
Return on investment5.25%
More ▼

Cash flow in JPYView more

In 2024, Hisamitsu Pharmaceutical Co Inc did not generate a significant amount of cash. However, the company earned 18.19bn from its operations for a Cash Flow Margin of 12.83%. In addition the company used 2.51bn on investing activities and also paid 16.69bn in financing cash flows.
Cash flow per share277.13
Price/Cash flow per share17.50
Book value per share3,730.09
Tangible book value per share3,642.09
More ▼

Balance sheet in JPYView more

Hisamitsu Pharmaceutical Co Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio3.53
Quick ratio3.14
Total debt/total equity0.0041
Total debt/total capital0.004
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)1.84%
Div growth rate (5 year)0.60%
Payout ratio (TTM)44.51%
EPS growth(5 years)-4.62
EPS (TTM) vs
TTM 1 year ago
11.90
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.